Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345376 | 0.78 | APP (0.52) | NFE2L2RELACA1NPC1RAB9A | |
| SCHEMBL5486754 | 0.78 | NFE2L2 (0.48) | NFE2L2RELACA1NPC1RAB9A | |
| SCHEMBL5486756 | 0.78 | NFE2L2 (0.48) | NFE2L2RELACA1NPC1RAB9A | |
| (E)-1,2-Di-P-Tolylethene SCHEMBL1305580 | 0.78 | NFE2L2 (0.74) | NFE2L2RELACA1NPC1RAB9A | |
| SCHEMBL318785 | 0.78 | NFE2L2 (0.74) | NFE2L2RELACA1NPC1RAB9A | |
| (E)-1,2-Di-P-Tolylethene SCHEMBL1305582 | 0.78 | NFE2L2 (0.74) | NFE2L2RELACA1NPC1RAB9A | |
| SCHEMBL318786 | 0.78 | NFE2L2 (0.74) | NFE2L2RELACA1NPC1RAB9A | |
| (E)-1,2-Di-P-Tolylethene SCHEMBL1793692 | 0.78 | NFE2L2 (0.74) | NFE2L2RELACA1NPC1RAB9A | |
| SCHEMBL5845622 | 0.77 | MAOB (0.50) | NFE2L2RELANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL373962 | 0.77 | MAOB (0.50) | NFE2L2RELANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943318-A | Synthesis method of chiral phenyl silanol and 1, 2-chiral disilicon compound | 宁夏大学 | 2022-01-18 | — | — | CN | disclosed |
| US-8153835-B2 | Fullerene derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090247777-A1 | FULLERENE DERIVATIVES | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247777-A1 | FULLERENE DERIVATIVES | SCO2, C1S, C1R | NFE2L2 321/4885RELA 1519/4885CA1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.